BRD4-mediated ER membrane contact creates functionally distinct mitochondria subtypes, Chen et al

Manuscript related data:
a. Supplemental tables (Table S1-7)
Table S1. FDA-drug repurposing screen, related to figure 1.
Table S2. CRISPR screening results for regulators of ERMCS, related to figure 3.
Table S3. BrU-seq data for SW480 cells treated with fedratinib for 30 min and 2 hr, related to Figures 3, S2 and S3.
Table S4. Metabolomics information for fedratinib-treated SW480 and HT1080 cells, related to Figure 5.
Table S5. Lipidomic information for fedratinib-treated SW480 and HT1080 cells and mitochondria, related to Figure 5.
Table S6. Whole cell and FAMS-sorted mitochondrial proteomics results in vehicle (DMSO) treated cells, fedratinib-treated cells. SPLICSLo and SPLICSHi mitochondria from vehicle and fedratinib-treated cells, related to Figure 6 and Figure S3.
Table S7. Nucleotide sequences used for primers and oligos, related to Figures 2, 3, and S3 and STAR Methods.
b. Source Blots and FAMS plots
c. Source statistical data for main figures (Figure 1-7)
d. Source statistical data for supplemental figures (Figure S1-7)
e. Supplemental movie (1-4)
1. Lattice light sheet imaging of SW480 treated with fedratinib
1. Lattice light sheet imaging of HT1080 treated with fedratinib
1. CLEM segmentation rendering of SW480 treated with fedratinib
1. CLEM segmentation rendering of HT1080 treated with fedratinib